3D9

3D9 is an agonist monoclonal antibody targeting the Thrombopoietin receptor (TPOR). Developed by researchers at The Scripps Research Institute and Zebra Biologics, it exhibits a unique property termed "receptor pleiotropism," where it induces a different cellular fate than the natural ligand, thrombopoietin. Specifically, in the context of acute myeloid leukemia (AML), 3D9 triggers the transdifferentiation of leukemic stem cells into functional natural killer (NK)-like cells. These induced killer cells express Granzyme B and Perforin, leading to the fratricidal destruction of neighboring AML cells. This effect is notably more potent in relapsed AML populations, which are enriched for stem-like cells. In healthy hematopoietic stem cells, 3D9 maintains the physiological function of TPOR by promoting megakaryocyte and platelet production without inducing the killer cell phenotype.

Other names

TPOR agonist antibody 3D9Clone 3D9Clone3D9Clone-3D9